Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.

Fiche publication

Date publication

août 2022

Journal

Clinical lung cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie

Tous les auteurs :
Mordant P, Brosseau S, Milleron B, Santelmo N, Fraboulet-Moreau S, Besse B, Langlais A, Gossot D, Thomas PA, Pujol JL, Ricordel C, Madelaine J, Lamy R, Audigier-Valette C, Missy P, Blons H, Barlesi F, Westeel V,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36180314

Résumé

Molecular profile of resected stage I-II non-small cell lung cancer (NSCLC) would help refine prognosis and personalize induction or adjuvant strategies. We sought to report the molecular profile of resected stage I-II NSCLC and analyzed the impact of epidermal growth factor receptor (EGFR) mutations on outcomes in a Western population.